Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel and Cisplatin PIPAC in Peritoneal Carcinomatosis
NCT04000906Phase 1Active, not recruiting
- Start
- Nov 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel in peritoneal carcinomatosis (PC). Primary endpoint: Maximal Tolerated Dose at 30 days. Started Nov 2020; status: active, not recruiting.
02
Drugs
paclitaxel
03
Conditions
peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT04000906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04000906.